Home/Biosimilar Atlas/Bevacizumab/Enzene Biosciences bevacizumab

Enzene Biosciences bevacizumab

Bevacizumab biosimilar developed by Enzene Biosciences (Alkem). Reference product Avastin.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Enzene Biosciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOFeb 2023permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
BevacizumabmoleculeEnzene Biosciencesdeveloper1 of 7markets0trials behind it5other products, same developer7rival developers in its markets

About Enzene Biosciences bevacizumab

Enzene received its bevacizumab permission in India in early 2023, initially for bowel cancer, with the other reference indications added in 2024. It is one of several antibodies Enzene has brought to the Indian market since 2021.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Enzene Biosciences Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Feb 2023
Application or permission
MF/BIO/23/000011; additional indications MF/BIO/24/000014
Indications as licensed
Colorectal cancer at permission; further reference indications added January 2024
Presentations
100 mg/4 mL and 400 mg/16 mL
Source
S011 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Enzene Biosciences bevacizumab holds an approval, these are the other bevacizumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO7Biocon Biologics (Jobevne / Abevmy / Krabeva), CuraTeQ Biologics (CuraTeQ bevacizumab), Dr. Reddy's Laboratories (Dr. Reddy's bevacizumab), Hetero (Hetero bevacizumab), Intas Pharmaceuticals (Intas bevacizumab), Reliance Life Sciences (Reliance Life Sciences bevacizumab), Zydus Lifesciences (Zydus bevacizumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Enzene Biosciences: Enzene Biosciences adalimumab, Enzene Biosciences pertuzumab, Enzene Biosciences ranibizumab, Enzene Biosciences teriparatide, Osqay / Enzene denosumab.

Chronology

Sources

All bevacizumab biosimilars

Planning bevacizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.